Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07419334 · ClinicalTrials.gov registry record · Phase 3
Study of ALK-001 on the Progression of Stargardt Disease
A Phase 3 study, sponsored by Alkeus Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 230
- Enrollment target
NCT07419334 is a Phase 3 study that is actively recruiting participants, run by Alkeus Pharmaceuticals. The registered enrollment target is 230 participants.
The verdict
NCT07419334, a Phase 3 study, is actively recruiting participants, sponsored by Alkeus Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 230 participants
- Enrollment target
Study Summary
This study evaluates the efficacy and safety of investigational study drug ALK-001 in participants 8 to 45 years of age, inclusive, with symptoms and signs of autosomal recessive Stargardt disease (STGD)
Interventions
- DRUG Placebo
- DRUG ALK-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2026-06 |
| Est. Completion | 2030-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07419334
The ClinicalTrials.gov registry entry for NCT07419334 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkeus Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07419334 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07419334 about?
NCT07419334 is a clinical study titled "Study of ALK-001 on the Progression of Stargardt Disease". This study evaluates the efficacy and safety of investigational study drug ALK-001 in participants 8 to 45 years of age, inclusive, with symptoms and signs of autosomal recessive Stargardt disease (STGD)
What is the current status of trial NCT07419334?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 230 participants. The study started on 2026-06. Estimated completion is 2030-12.
What interventions are being tested in trial NCT07419334?
The interventions under investigation include: Placebo (DRUG), ALK-001 (DRUG).
Who is sponsoring clinical trial NCT07419334?
This trial is sponsored by Alkeus Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.